Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Genomic residual disease in AML prior to allo-SCT: fate or early intervention opportunity?

Christopher Hourigan of the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, gives his press briefing on the late-breaking abstract of genomic evidence of residual disease in acute myeloid leukemia (AML) patients in remission prior to allogeneic stem cell transplant. He discusses whether this is fate or an opportunity for early intervention. This press briefing was recorded at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.